November 19, 2012 / 1:40 PM / 5 years ago

CORRECTED-BRIEF-Pfizer says fibromyalgia drug met main goal in late-stage study

(Corrects headline to say study met main goal, not failed it) Nov 19 (Reuters) - Pfizer : * Reports top-line results of a phase 3 study evaluating pregabalin controlled-release as treatment for patients with fibromyalgia * Phase 3 study indicates that pregabalin CR had a statistically significant positive effect versus placebo in primary endpoint * This study is the second of three phase 3 studies of the pregabalin CR formulation to report top-line findings * Top-line results of the first study in adults with partial onset seizures with epilepsy did not meet its primary endpoint * Says the final study in post-herpetic neuralgia is ongoing * Source text * Further company coverage

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below